It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
INPP4B suppresses PI3K/AKT signaling by converting PI(3,4)P2 to PI(3)P and INPP4B inactivation is common in triple-negative breast cancer. Paradoxically, INPP4B is also a reported oncogene in other cancers. How these opposing INPP4B roles relate to PI3K regulation is unclear. We report PIK3CA-mutant ER+ breast cancers exhibit increased INPP4B mRNA and protein expression and INPP4B increased the proliferation and tumor growth of PIK3CA-mutant ER+ breast cancer cells, despite suppression of AKT signaling. We used integrated proteomics, transcriptomics and imaging to demonstrate INPP4B localized to late endosomes via interaction with Rab7, which increased endosomal PI3Kα-dependent PI(3,4)P2 to PI(3)P conversion, late endosome/lysosome number and cargo trafficking, resulting in enhanced GSK3β lysosomal degradation and activation of Wnt/β-catenin signaling. Mechanistically, Wnt inhibition or depletion of the PI(3)P-effector, Hrs, reduced INPP4B-mediated cell proliferation and tumor growth. Therefore, INPP4B facilitates PI3Kα crosstalk with Wnt signaling in ER+ breast cancer via PI(3,4)P2 to PI(3)P conversion on late endosomes, suggesting these tumors may be targeted with combined PI3K and Wnt/β-catenin therapies.
The PI(3,4)P2 4-phosphatase, INPP4B, functions as a tumour suppressor in triple negative breast cancer. Here, the authors show that INPP4B enhances proliferation and growth of PIK3CA-mutant ER+ breast cancers by promoting PI3Kα-dependent late endosome formation and trafficking that leads to the activation of Wnt/β-catenin signalling.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Oorschot Viola M J 2 ; Schittenhelm, Ralf B 3
; Nguyen, Elizabeth V 1 ; Hamila, Sabryn A 1 ; Rynkiewicz Natalie 4 ; Gurung Rajendra 1 ; Eramo, Matthew J 1 ; Sriratana Absorn 1 ; Fedele, Clare G 5 ; Caramia Franco 6
; Loi Sherene 6
; Kerr, Genevieve 7 ; Abud, Helen E 7
; Ramm Georg 8
; Papa Antonella 1
; Ellisdon, Andrew M 9 ; Daly, Roger J 1
; McLean, Catriona A 10
; Mitchell, Christina A 1
1 Monash University, Cancer Program, Biomedicine Discovery Institute, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Monash University, Department of Biochemistry and Molecular Biology, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
2 Monash University, Monash Ramaciotti Centre for Cryo Electron Microscopy, a Node of Microscopy Australia, Victoria, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Electron Microscopy Core Facility, European Molecular Biology Laboratory, Heidelberg, Germany (GRID:grid.4709.a) (ISNI:0000 0004 0495 846X)
3 Monash University, Monash Proteomics and Metabolomics Facility, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
4 Monash University, Department of Biochemistry and Molecular Biology, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Babraham Institute, Cambridge, UK (GRID:grid.418195.0) (ISNI:0000 0001 0694 2777)
5 Monash University, Department of Biochemistry and Molecular Biology, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); University of Melbourne, Peter MacCallum Cancer Centre, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
6 University of Melbourne, Peter MacCallum Cancer Centre, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
7 Monash University, Development and Stem Cells Program, Biomedicine Discovery Institute, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Monash University, Department of Anatomy and Developmental Biology, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
8 Monash University, Cancer Program, Biomedicine Discovery Institute, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Monash University, Department of Biochemistry and Molecular Biology, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Monash University, Monash Ramaciotti Centre for Cryo Electron Microscopy, a Node of Microscopy Australia, Victoria, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
9 Monash University, Cancer Program, Biomedicine Discovery Institute, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Monash University, Department of Biochemistry and Molecular Biology, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Monash University, Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
10 Department of Anatomical Pathology, Alfred Hospital, Prahran, Australia (GRID:grid.1623.6) (ISNI:0000 0004 0432 511X)




